 The primary objective of CRAD001M2305 is to report the long-term effects of everolimus treatment on height, weight and sexual development using Tanner Stages in children and adolescents with Tuberous Sclerosis Complex TSC-associated with Subependymal Giant Cell Astrocytoma SEGA. The study will monitor the growth and development of pediatric patients with TSC-associated SEGA, previously enrolled in CRAD001M2301 until they reach Tanner Stage V, or until age 16 for females or 17 for males whichever occurs first. 